U.S. FDA Tells India's Ranbaxy To Assess Plants

The U.S. drug regulator has asked India's Ranbaxy Laboratories to immediately assess whether its plants making drugs for the U.S. market meet standards, the Economic Times newspaper reported on Friday.

Ranbaxy, India's top drugmaker which is majority owned by Japan's Daiichi Sankyo, in December said a U.S. unit had received a warning letter from the U.S. Food and Drug Administration (FDA) on violations of good manufacturing practices. A Ranbaxy spokesman said he had no fresh comment beyond that made in a statement issued on Dec. 24 in the wake of the FDA letter, where Ranbaxy said it would cooperate with regulators and remained committed to comply with standards.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.